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Background/aim: Multiple sclerosis (MS) is a common neurological disorder that can be a leading cause of nontraumatic disability in
several countries. Recent reports have indicated a moderate to high risk of MS in European countries. In this study, we examined the
prevalence of MS in a well-defined urban population of provincial center in Sivas Province in Turkey.
Materials and methods: This study sampled all registered residents of urban areas of provincial center in Sivas Province in April 2017
and 2018 January. All the included patients met the McDonald 2010 criteria. Medical records were reviewed, including all available
previously acquired magnetic resonance imaging data. All patients were subsequently subjected to neurologic examination to confirm
the MS diagnosis.
Results: We identified 21 possible MS patients, with MS diagnosis confirmed in 19. The prevalence of MS was 288 per 100,000 inhabitants.
Conclusion: For future studies, these high ratio results can be used in regional and national comparisons to determine cofactors
contributing to the high prevalence of MS in our region and can help health-decision makers to better plan healthcare policies to
improve neurological services and awareness about multifaceted clinical presentations of MS.
Key words: Multiple sclerosis, prevalence, Sivas

1. Introduction
Multiple sclerosis (MS) is a common neurological disorder
that can lead to significant physical disability with more
than 30% of MS patients within 20 to 25 years (1). It is
the leading cause of nontraumatic neurologic disability in
young adults in many countries (2,3). Because of the high
prevalence of MS in Caucasians, the epidemiology of MS
has been extensively studied and reported primarily for
Western countries (4,5). According to a recent review of
epidemiologic studies related to MS (2,6), the estimated
number of people with MS increased from 2.1 million in
2008 to 2.3 million in 2013, and the estimated female to
male ratio of this disorder increased from 1.4:1 to 2.3:1.
Most MS patients experience clinical onset between
the ages of 20 and 40 years, with a peak age of onset of
24 years in women and 25 years in men (7,8), although
clinical onset rarely occurs as early as the first years of
life or as late as the seventh decade (8) Several authors
have reported a higher frequency of MS among women,
especially during pubertal age (9). The prevalence of
MS is higher in Northern Europe, America, and South

Australia than in Asia and Africa; in addition, there was
an increase in the prevalence of MS in other parts of the
world, albeit with a low prevalence (10–12). The variation
in prevalence depends on several geographical, genetic,
and environmental factors (13).
The occurrence of MS varies geographically by latitude
(14). The prevalence of disease is 140/100,000 to 108/100,000
in North America and Europe, and these rates decrease to
2.1/100,000 to 2.2/100,000 in sub-Saharan Africa and East
Asia. In the same prevalence registrations, the highest rate,
189/100,000, was found in Sweden, whereas it is 22/100,000
in Albania. MS has a remarkably uneven distribution across
the world, with peak prevalence ratios and incidence rates
found in the northern hemisphere, where the climate is
temperate and income rates are high. In contrast, MS is
uncommon in equatorial and tropical countries, particularly
among those with low income rates. In addition, in the
context of environmental influences, the change in MS
prevalence may be related to the population shift from rural
to urban areas after industrial development, which causes
important changes in environmental factors (15,16).
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As defined by Kurtzke (17), Europe has a high
prevalence of MS (≥30/100,000), and it contains more than
half of the global population of those diagnosed with MS
(18). Nevertheless, much uncertainty remains regarding
how the risk of MS varies among European populations.
The aim of this study was to systematically review the
prevalence and incidence of MS across Europe. However,
recent reports have shown increases in the prevalence of
MS in Greece, Iran, and other Middle Eastern countries
around Turkey. Turkey is considered to have a high risk of
MS, with an estimated prevalence of more than 100 cases
per 100,000 inhabitants and northern Turkey may be a
high-risk area for MS (19). Considering the limitations of
the existing data, the prevalence and incidence of MS in
the Central Anatolia region of Turkey are unknown.
Relevant epidemiological data may help to have
a better understanding of the risk factors of MS and
may contribute to the development of new therapeutic
modalities. For this purpose, the McDonald 2010 criteria
were the most preferred criteria for the diagnostic
assessment of MS during the study period (20). Given this
situation, MS mortality, incidence, and prevalence data
and their evolution over time in Turkey are important for
the development of screening and management strategies
to reduce the healthcare burden. The prevalence of MS in
Sivas Province in Central Anatolia has not been reported
previously. With its high altitude and relatively low
migration rates, Sivas is an ideal region to be studied as
compared with the other regions of Anatolia. The present
study was designed to estimate the prevalence of MS using
the McDonald 2010 criteria in urban regions of provincial
center of Sivas.
2. Material and methods
This community-based cross-sectional study was
conducted between April 2017 and January 2018, in urban
regions of provincial center of Sivas province, located in
the eastern part of Turkey. Approval of the study protocol
was obtained from the Human Ethics Committee of our
University (Registry No. 2016-05/32, dated 27.05.2016).
Written informed consent was obtained from the study
population.
The distribution and frequency of MS were assessed by
estimates of prevalence and incidence. Prevalence refers to
the proportion of a population with the disease at or during
a specified time, whereas incidence refers to the proportion
of new cases arising over a specific period. Prevalence
reflects the “stock” of patients, whereas incidence reflects
the dynamic dimension of the disease (21).
2.1. Study area
Sivas is a city located between the latitudes 38°42ʹ N and
40°16ʹ N, and the longtitudes 35°50ʹ E and 38°14ʹ E. The
altitude of the city is 1285 m. Sivas has a dry summer

continental climate, with warm and dry summers and cold and
snowy winters. The population is homogeneously Turkish,
and the middle-poor class dominates socioeconomically. It
receives little immigration from other Turkish cities.
Less exposure to sunlight due to the long winter periods
and the style of traditional clothing may be the cause
of a high incidence of vitamin D deficiency among the
population. The duration of exposure to sunlight in Sivas
is below the Turkish average. The population has a habit of
staying indoors, and summer vacation in warmer climates
is also a rare activity. Consumption of red meat and high
carbohydrates is a common nutritional habit as part of their
general lifestyle. Along with this eating habit, the lack of
consumption of fresh vegetables and fish is also a problem
of traditional nutrition. All these characteristics may
contribute to the development and progress of MS along
with vitamin D deficiency, which may also be a predisposing
factor for MS.
2.2. Study population
According to the 2016 census, provincial center of Sivas has a
population of 365,135 in the urban region. The study sample
was randomly selected from 22 administrative districts using
a systematic sampling method. The survey involved 274,704
individuals older than 15 years, and a sample of 6596 (3280
males and 3316 females) was chosen.
The sample size was calculated using the equation
proposed for prevalence research by Naing et al. (22). To
calculate the sample size for a prevalence study, the expected
prevalence is required. Based on a previous Turkish research
(19), the expected prevalence of MS was accepted as 0.001.
Therefore, Naing et al.’s (22) equation with the degree of
precision (d) = 0.000763 produced a sample size of 6596 in a
population size of 274,704.
In this study, to select the neighborhoods in the study
region and the streets in these neighborhoods, researchers
benefited from the results of a dissertation thesis including
socioeconomic features of urban regions of provincial center
of Sivas (7). Neighborhood selection was determined by a
cluster sampling method. The streets in each neighborhood
were considered to be a cluster, and the streets were selected
at a rate of 0.20 and 80%.
2.3. Face-to-face survey
Information was collected with a questionnaire through
face-to-face interviews with the 6596 respondents or with a
household member for those who were illiterate.
The questionnaire assessed sociodemographic and
selected clinical characteristics: sex, age, birthplace, family
history, smoking, socioeconomic status, occupation
(employed, unemployed, retired, and housewife), age at first
diagnosis, disease duration, subtypes of disease (relapsing
remitting MS, secondary progressive MS, and primary
progressive MS), treatment, and expanded disability status
scale (EDSS).
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To screen for neurologic findings of MS, we questioned
participants about their relapse symptoms and signs of MS.
MS relapse was defined by the 2010 McDonald criteria as
“patient-reported symptoms or objectively observed signs
typical of an acute inflammatory demyelinating event in
the CNS (central nervous system), current or historical,
with duration of at least 24 hours, in the absence of fever
or infection” (20).
The patients’ disability status was evaluated according
to the EDSS (6). This scale reflects the rate of disability
from 0 to 10 obtained by the evaluation of functional
systems; that is, an EDSS score of 4, 7, 8, and 10 represents
an ambulatory patient without assistance, unable to walk
more than 5 m with assistance, bed and chair dependency,
and morbidity due to MS.
2.4. Neurologic evaluation
In the second phase of data collection, the clinical aspects of
MS in all subjects with clinical and suspected MS findings
were evaluated in our neurology outpatient service.
Patients who were followed up with an MS diagnosis
were referred to the clinic and evaluated with clinical,
radiologic, and laboratory findings. Participants with
previously confirmed MS and newly suspected MS were
evaluated according to the 2010 McDonald criteria (20).
Patients who did not meet the clinical and radiologic
criteria for disease were excluded.
2.5. Statistical analysis
The distribution of characteristics of participants
was presented as numbers, percentages, and means.
Mann–Whitney and chi-square tests were performed
for demographic and selected clinical data of the study
population as appropriate. IBM SPSS Statistics (version
23.0) was used for all analyses. A P-value of less than 0.05
was accepted as significant.
3. Results
The baseline characteristics of the study population are as
shown in Table. During the study period, 21 of the 6595
subjects were found to have MS or MS-related symptoms.
Of these 21 patients, 20 had been diagnosed previously
and one diagnosed by our research team as a new case;
however, in two of the previously diagnosed patients,
after neurologic examination and evaluation of previous
medical records and laboratory results, we did not confirm
MS disease and instead diagnosed cerebrovascular disease
and neuromyelitis optica (NMO). Ultimately, we analyzed
the clinical data of 19 MS patients. The prevalence of MS
was calculated as 288/100,000.
Of 18 MS patients, 9 were followed by our neurology
service, 5 were diagnosed in our neurology service but
followed in another health institution, 1 was diagnosed
and followed by another health institution in other Turkish
cities, and 3 did not complete follow-up.
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Table. Selected demographic and clinical data of the study
population.
Female (n = 11)

Male (n = 8)

Age (y)

40 (23–70)

38 (23–47)

Birth place
Sivas
Other Turkish city
Other country

9 (81.8%)
1 (9.1%)
1 (9.1%)

8 (100%)

Family history
Yes
No

3 (27.3)
8 (72.7%)

1 (12.5%)
7 (87.5%)

2 (18.2%)
9 (81.8%)

5 (62.5%)a
2 (25.0%)
1 (12.5%)

4 (36.4%)
7 (63.6%)

2 (25.0%)
6 (75.0%)

Smoking
Current
Never
Past
Socioeconomic status
Low
Moderate
Occupation
Employed
Retired
Unemployed
Housewife

3(27.3%)
2 (18.2%)
6 (54.5%)

4 (50.0%)
3 (37.5%)
1 (12.5%)

Age at first diagnosis (y)

28 (19–43)

26 (18–35)

Disease duration (y)

8 (1–35)

11.5 (1–20)

Subtypes of disease
RRMS
SPRS
PPMS

7 (63.6%)
3 (27.3%)
1 (9.1 %)

6 (75.0%)
1 (12.5%)
1 (12.5%)

Treatment
Yes
No

10 (90.9%)
1 (9.1%)

7 (87.5%)
1 (12.5%)

EDSS

1 (0.5–8)

2.5 (0.5–8)

Data are presented as median (min–max) or number (percentage).
P < 0.05 vs. female. Other variables were found to be similar (P
> 0.05).
Abbreviations: RRMS, relapsing-remitting multiple sclerosis;
SPMS, secondary progressive multiple sclerosis; PPMS, primary
progressive multiple sclerosis; EDSS, expanded disability status
scale.
a

The median ages of the female and male patients were
similar (P > 0.05). The birthplace of nearly all the study
population was Sivas. Among the study population,
4 (21%) patients had a family history of MS. The active
smoking rate was significantly higher in male patients
(62.5% vs. 18.2%; P < 0.05). The socioeconomic status
and subtypes of disease of female and male patients were
comparable (P > 0.05). Most of the female patients were
housewives, and half of the male patients were actively
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working. Of both female and male patients, the ages at
first diagnosis, disease duration, and EDSS values were
found to be similar (P > 0.05). Nearly 90% of the study
population was receiving treatment for MS.
4. Discussion
In the current survey, we screened 6596 subjects aged 15
years and older in the urban areas of provincial center of
Sivas, which is in a high-altitude region of eastern Anatolia.
We confirmed the diagnosis of MS in 19 subjects, and the
MS prevalence was calculated as 288/100,000. However,
in the first phase of the study, two patients were found
as under MS follow-up, and in the neurologic evaluation
phase, we could not confirm their diagnosis as MS. Their
diagnoses were changed to cerebrovascular disease and
NMO.
In the current study, there were more female than male
MS subjects (11 vs. 8). The ages of the female and male
participants were similar. All subjects were predominantly
from Sivas. This is an important point that increases the
reliability of our data about the MS prevalence in Sivas.
A closed lifestyle and limited migration as local regional
features may be predisposing genetic factors for MS.
Although there were small case numbers, family history
was more pronounced in female subjects (3 vs. 1 subject).
Current smoking in male subjects was meaningful
compared with female subjects. All patients were mainly
from a moderate socioeconomic class. Being a housewife
and being employed were meaningful in female and
male subjects, respectively. Age at first diagnosis was in
accordance with other studies in Turkey and European
countries (23,24). There was no meaningful difference
between female and male subjects in terms of disease
duration, subtype of disease, use of treatment, or EDSS
value. These findings, overall, are in accordance with our
experience in MS diagnosis, management, and follow-up.
Although a few Turkish studies exist on the prevalence
of MS and related factors influencing the disease, it is
obviously necessary to carry out further regional and
countrywide studies and differentiate the influence of
factors, including geographic, socioeconomic, and lifestyle
variables.
Knowledge about distribution of MS patients in
the country may cause an important impact on the
development of new strategies to decrease the burden
of this chronic condition on the healthcare system with
rational use of national resources. At the national level,
a heterogeneous distribution of cases over a territory
requires adequate distribution of healthcare resources.
Moreover, determination of the geographical variation in
MS prevalence would lead to novel ways that research can
further explore the spatial or environmental conditions
affecting healthcare for chronic neurologic diseases

(25,26). The MS prevalence of 288/100,000 found in
our study is much higher those than reported in studies
conducted in other regions or cities in Turkey at various
dates. In a prevalence study involving six cities in the
Central Black Sea Region of Turkey, the MS prevalence
was found to be 43.2/100,000 in 2017. In that study, the
MS prevalence of 46.5/100,000 was reported in Samsun
Province. Those data including 1787 MS patients were
obtained from hospital records of Samsun, Sinop, Ordu,
Amasya, Tokat, and Çorum Provinces over a 10-year
period (23). In a door-to-door epidemiological field
study conducted by Alp et al. (27), the prevalence of MS
in Kars Province of northeastern Turkey was reported as
69/100,000. In another Turkish study in three cities of the
Black Sea region, conducted via door-to-door interviews
in rural areas, the MS prevalence was 61/100,000,
41/100,000, and 53/100,000 in Kandıra, Gevye, and
Erbaa counties, respectively (24). In a prevalence study
conducted in İstanbul in 2006 by the same researchers, the
MS prevalence was found to be 101.4/100,000 (19).
In studies conducted around the world, the prevalence
of MS has been reported to be lower in Siberia, European
Russia, Macedonia, Bulgaria, Greece, China, Japan,
and the Middle East (5). The lowest rate in the world is
in Malta (4/100,000) (28). A higher frequency of MS is
consistently found in Nordic countries (28–31), northern
parts of Western Europe, and North America, whereas
lower frequencies of MS have been reported in Asia,
the Middle East, and Africa (17,32–34). The highest
prevalence rates found in studies conducted in other
European cities are 203/100,000 in the United Kingdom
(35), 203/100,000 in Norway (34), 215/100,000 in Sweden
(36), 175/100,000 in Germany (37), 170/100,000 in France
(38), and 290/100,000 in Northwest Ireland (39). The
highest reported rate in the United States is 192/100,000
(40). The highest reported rate in the world was found in
Orkney, Scotland, at 410/100,000 (41). In recent decades,
many studies have reported an increasing prevalence of
MS among various parts of the world, including Sweden,
Finland, Japan, and Iran (42–45), whereas other studies
found a more stable prevalence (46). The reason for the
apparent increase in some studies is not known but may
be a result of improvements in diagnostic imaging or
an increased focus on MS in association with increased
availability of effective treatment (47).
Multiple factors have the potential to contribute to
the increase in MS prevalence (48–51). First, an actual
increase, due to underdetermined factors, in the frequency
of MS is possible. Second, improvements in diagnosis and
the incorporation of magnetic resonance imaging (MRI)
and new diagnostic criteria may result in earlier diagnosis
and improved detection of cases that are clinically milder
(52). Third, case detection might be increased due to
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general improvement in healthcare services and awareness
of the condition. Finally, an increase in long-term survival
might be explained by improved general medical care and
the possible beneficial effects of disease-modifying therapy
(53).
Prevalence studies conducted thus far have shown
that MS prevalence differs by geography and increases
especially as the distance from the equator increases.
However, rates below the estimates were also observed
in places far from the equator, where the prevalence was
expected to be high. This was attributed to the fact that
the habit of eating seafood is protective against the disease
(54). From this point of view, it seems that intake of
vitamin D from sunlight or via the oral route is decreasing
the frequency of disease (55). There are also places in the
world where the prevalence rates are significantly higher
than the general distribution in different regions of this
country, especially in Europe and America. This difference
is reported to be due to the local genetic characteristics
of the population, rather than environmental factors
such as nutrition and infection. A detailed investigation
of the environmental factors and genetic characteristics
of etiology in residential areas with high prevalence will
provide a better understanding of the etiopathogenesis of
the disease.
In cities with less migration of people, marriage within
the same community may modify the genetic basis of the
population for the development of some chronic diseases,
including MS. Even though there is a high amount of
sunlight in the study area, both traditional habit and
dressing for protection from cold as well as a preference
for an indoor environment in daily life can create a
deficiency of vitamin D, which may be an environmental
factor that plays a role in MS pathology. In addition, the
fact that vitamin D is not taken with food (in addition to a
preference for vegetables, seafood, and fresh fruit instead
of red meat, saturated fat, and carbohydrate) may also
contribute to the high prevalence of MS (55,56).
In summary, the number of studies on the prevalence
of MS disease in Turkey is very low. The rates found in
these studies are very low compared with the results of

this study. The results obtained in Sivas Provincial Center,
which is a Central Anatolian city, are the highest ever
reported in Turkey. This result may depend on the closed
genetic characteristic of the region but may also be a result
of environmental factors, nutritional characteristics, and
lifestyle-related characteristics. The values obtained in
this study will be useful in planning further studies as well
as in elucidating the etiopathogenesis of the disease and
determining appropriate treatment strategies. Healthcare
and support services have improved compared with 2008
(e.g., increased numbers of neurologists, MRI machines).
Regarding the methodological strengths and
limitations of the current study, the cross-sectional design
has limitations in terms of causal interpretation of clinical
data. In addition, it does not account for the change of
prevalence because of time. This study has significant
strengths, including neurologic evaluation performed in
the same outpatient service with a similar setup, use of
only the McDonald 2010 criteria for the final diagnosis
of MS patients, a small rate of migration to Sivas, and the
opportunity to enroll subjects with the same genetic and
environmental background.
Our study was a population-based, cross-sectional
study and the first of its kind to provide a considerably
accurate estimate of the prevalence of MS in Sivas. To the
best of our knowledge, there are no previously reported
data on the prevalence in our region. This study was
conducted because of the limited number of studies on
the prevalence of MS in Turkey, the different prevalence
rates across regions, and the lack of studies focusing on
the Central Anatolian region. During the study period, we
found 2 subjects with a wrong diagnosis of MS, suggesting
that in Sivas, there is an important need to increase
neurologic healthcare and health workers’ awareness of
MS and other chronic neurologic diseases. Our results
can be used in future studies of regional and national
comparisons to determine cofactors that contribute to
the high prevalence of MS in our region and can also help
health-decision makers to better plan healthcare policies
to improve neurologic services and awareness about the
multifaceted nature of MS.
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